Dyania Health develops the Synapsis AI platform to extract and analyze insights from structured and unstructured clinical data. The platform automates reading of physician notes, pathology reports, lab results, and supports workflows such as clinical trial pre-screening and chart reviews. Dyania trained a large language model on annotated electronic medical records during the COVID-19 pandemic and operates the solution locally with HIPAA and GDPR safeguards. Cleveland Clinic has been an early adopter and is implementing Synapsis enterprise-wide after a year-long collaboration, including work with its Heart, Vascular, and Thoracic Institute. Leadership includes executives with backgrounds at Amazon and Bloomberg. The company, based in Atlanta, Georgia, with 11–50 employees, plans to use recent funding to enhance product offerings and scale operations. Dyania Health builds natural language processing technology that applies a prescriptive, rule-based approach using in-house medical and scientific expertise. Its platform is HIPAA compliant and is designed to drive clinical research, speed drug development, and improve patient outcomes. The company emphasizes a team of NLP data scientists, physicians, and serial drug inventors with experience at institutions including UCLA, Harvard Medical School, Northwell Health, and Kite Pharma. Dyania intends to use new funding to scale algorithms and engineering, advance product development, and expand pharmaceutical client support. The company was founded in 2019 and is based in New York City. Financially, it completed a seed fundraising event in 2022 to support those growth priorities.

Total raised

$15M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2024